Detalhe da pesquisa
1.
Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice.
BMC Cancer
; 21(1): 73, 2021 Jan 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33451293
2.
Real-world effectiveness and safety of ixazomib-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma.
Ann Hematol
; 99(5): 1049-1061, 2020 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-32236735
3.
Dynamics of tumor-specific cfDNA in response to therapy in multiple myeloma patients.
Eur J Haematol
; 104(3): 190-197, 2020 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-31763708
4.
Venetoclax plus bortezomib and dexamethasone in heavily pretreated end-stage myeloma patients without t(11;14): A real-world cohort.
Hematol Oncol
; 38(3): 412-414, 2020 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-32323881
5.
Single-agent venetoclax induces MRD-negative response in relapsed primary plasma cell leukemia with t(11;14).
Am J Hematol
; 94(1): E35-E37, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30370955
6.
Ixazomib, Lenalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma in Routine Clinical Practice: Extended Follow-Up Analysis and the Results of Subsequent Therapy.
Cancers (Basel)
; 14(20)2022 Oct 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-36291949
7.
Cytarabine + G-CSF is more effective than cyclophosphamide + G-CSF as a stem cell mobilization regimen in multiple myeloma.
Bone Marrow Transplant
; 54(7): 1107-1114, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-30459429
8.
Limited efficacy of daratumumab in multiple myeloma with extramedullary disease.
Leukemia
; 36(1): 288-291, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34247197
9.
10 years of experience with thalidomide in multiple myeloma patients: report of the Czech Myeloma Group.
Leuk Res
; 37(9): 1063-9, 2013 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-23845888